Cardiff Oncology, Inc. CRDF

Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.

Under the terms of the Amendment, all disputed issues are resolvedSAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached a settlement and amended their 2017 Exclusive License Agreement, resolving all outstanding disputes between the two companies related to the global rights for onvansertib, Cardiff's lead PLK1 inhibitor drug candidate, and establishing

SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that Mani Mohindru, Ph.D. will participate in two upcoming conferences. Details of the company’s participation are as follows: 8th Annual RAS-Targeted Drug Development Summit Advancing PLK1 Targeted Therapy to Transform Outcomes in RAS Mutant Metastatic Colorectal Cancer; Tuesda

By John Vandermosten, CFA NASDAQ: CRDF READ THE FULL CRDF RESEARCH REPORT 2Q:26 Financial Results Cardiff Oncology, Inc. (NASDAQ: CRDF) reported second quarter 2026 financial and operational results in a press release and Form 10-Q filing with the SEC on August 11 th , 2026. The company highlighted the Phase II data presented at ASCO at the end of May and shared its plans to initiate its pivotal

Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRC Following successful End-of-Phase 2 meeting with FDA, Company aligned on key elements of registrational trial; plans to initiate study in Q1 2027, subject to securing additional financing Completed $10 million Registered Direct offering, extending cash runway SAN DIEGO, Aug. 11, 2026 (GLOBE NEWSWI

Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor TakeawaysCardiff Oncology (NASDAQ:CRDF) expects to raise approximately $10 million in gross proceeds through a registered direct offering.

SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per share and accompanying

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Cardiff Oncology, Inc. (NASDAQ:CRDF) is one of the most promising stocks on our list. TheFly reported on June 5 that Lucid Capital analyst Christopher Liu reduced the price target on CRDF to $4 from $10 while reaffirming a Buy rating. […]

By John Vandermosten, CFA NASDAQ: CRDF READ THE FULL CRDF RESEARCH REPORT Updated Results from CRDF-004 Cardiff Oncology, Inc. (NASDAQ: CRDF) presented interim data from its CRDF-004 trial at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The event took place from May 29 th to June 2 nd, 2026. The oral presentation was entitled Onvansertib plus standard-of-care

-​ The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program -​ -​ 30 mg onvansertib + FOLFIRI/bevacizumab arm showed a dose-dependent improvement in efficacy, including confirmed ORR of 72.2% compared to 42.1% for SoC -​ -​ Median PFS has not been reached in either 20 or 30 mg onvansertib + FOLFIRI/bevacizumab arm, with nine of the 14 patients remaining on treatment in these arms -​ - Onvansertib

Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia," "Kazia Therapeutics" or the "Company"), a clinical-stage oncology company advancing therapies designed to reprogram cancer biology and overcome treatment resistance, today announced the appointment of James Levine as Chief Financial Officer, effective June 1, 2026. Mr. Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies.

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026. Details of the presentation can be found below. Format: Fireside ChatPresenter: Mani Mohindru, PhD (President and CEO) Date: 06/04/2026 T